SB Execs: More Pie, Please
Executive Summary
SmithKline's middle managers aren't particularly happy with their financial stake in the new Glaxo SmithKline. Thanks to a new patent on clavulanic acid, SB's #2 drug which was supposed to lose patent protection in 2002, and the withdrawal of a key competitor to SB's new diabetes drug rosiglitazone, SB will probably be providing most of the near-term earnings growth to the combined company. But SB shareholders only get 41% of the combined company. SB employees will therefore be sharing the earnings of their company, reflected in the value of their options, disproportionately with Glaxo employees.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.